WS
CTIC

Wedbush Securities’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Wedbush Securities’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,600
Closed -$15K – 1053
2020
Q2 		$15K Hold
12,600
– – ﹤0.01% 947
2020
Q1 		$12K Buy
+12,600
New +$14.4K ﹤0.01% 870

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedbush Securities's CTIC Position: Q3 2020 in Review

Wedbush Securities sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2020, closing a stake of 12,600 shares — an estimated $15K sold.

Wedbush Securities first reported a position in CTIC in Q1 2020 and held it in 2 quarters. The position peaked at $15K in Q2 2020. 38 funds tracked by Wall St. Rank hold CTIC as of Q3 2020.

  • Wedbush Securities reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2020 after selling out during the quarter.
  • Wedbush Securities sold 12,600 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2020, an estimated $15K.
  • Wedbush Securities first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2020 and held it in 2 quarters.
  • Wedbush Securities's CTI BioPharma Corp. (DE) Common Stock position peaked at $15K in Q2 2020.
  • 38 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.